The Chemotherapy Foundation Symposium

The Chemotherapy Foundation Symposium XXVII

TUESDAY, NOVEMBER 10

		PEDIATRIC ONCOLOGY
		Chair: Conrad Fernandez, MD
1:45		HIGHER RISK FAVORABLE HISTOLOGY IN WILMS TUMOR
		David Dix, MD
2:00		LOW-RISK RHABDOMYOSARCOMA
		David Walterhouse, MD
2:15		OPTIMIZING TREATMENT FOR RESECTABLE OSTEOSARCOMA
		Neyssa Marina, MD
2:30		NEW INTERNATIONAL PROTOCOL FOR PATIENTS WITH INTRA-OCULAR RETINOBLASTOMA
		Ira Dunkel, MD
2:45		NEW APPROACHES TO THE TREATMENT OF CHILDHOOD NASOPHARYNGEAL CARCINOMA
		Carlos Rodriguez-Galindo
3:00		Coffee Time
3:15		HEMATOPOIETIC CELL TRANSPLANTATION FOR NEUROBLASTOMA
		Sandeep Soni, MD
3:30		KIR INCOMPATIBILITY IN UNRELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION FOR PEDIATRIC ACUTE MYELOGENOUS LEUKEMIA
		Robert Iannone, MD
3:45		INTRAVENOUS ASPARAGINASE IN PEDIATRIC HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA
		Anne Angiolillo. MD
4:00		UPDATE ON THE MANAGEMENT OF RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA
		Susan Rheingold, MD
4:15		LATE EFFECTS OF PEDIATRIC CANCER TREATMENT
		Peter Manley, MD
4:30		NEUROCOGNITIVE FUNCTION IN CHILDREN TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA
		Naomi Winick, MD
4:45		FUNGAL INFECTIONS IN PEDIATRIC PATIENTS
		Theoklis Zaoutis, MD
5:00		THROMBOSIS IN CANCER PATIENTS
		Anne Hurlet, MD
7 -9 pm		DINNER AND SPECIAL PRESENTATION
		MANAGEMENT OF THE ADOLESCENT OR YOUNG ADULT WITH CANCER
		Robet J. Arceci, MD, PhD
		PROGRESS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
		Archie Bleyer, MD

WEDNESDAY, NOVEMBER 11
7:00am		BREAKFAST WITH THE PROFESSORS
		LENALIDOMIDE: AN EMERGING TREATMENT OPTION IN CLL
		Alessandra Ferrajoli, MD
		HIGH DOSE LENALIDOMIDE IN AML OF THE ELDERLY
		Ravi Vij, MD
8:00		WELCOME
		Steven Burakoff, MD, Janice L. Gabrilove, MD, Edward P. Ambinder, MD
		MORNING SESSION
		HEMATOLOGIC MALIGNANCIES
		Moderators: Janet Cuttner, MD, Janice L. Gabrilove, MD, Kanti Rai, MD
		MYELOPROLIFERATIVE/MYELODYSPLASTIC DISORDERS
		New Approaches and New Agents
8:10		NEW THERAPEUTIC OPTIONS IN MYELOPROLIFERATIVE NEOPLASMS
		Ronald Hoffman, MD
8:40		FRONTLINE AND SALVAGE STRATEGIES IN MYELODYSPLATIC SYNDROME
		Hagop Kantarjian, MD
8:55		JAK2 IN HEMATOPOIESIS AND STATUS OF ANTI-JAK2 TRIALS
		Richard Silver, MD
9:10		TREATMENT OF HIGH RISK AML
		Janice Gabrilove, MD
9:25		LOMUSTINE (CCNU) WITH IDARUBICIN AND CYTARABINE IN ELDERLY PATIENTS WITH AML
		Arnaud Pigneux, MD
9:40		REVISITING MAINTENANCE THERAPY IN AML
		Gail Roboz, MD
9:55		BENDAMUSTINE IN CLL
		Bruce Cheson, MD
10:10		Coffee Time
10:40		MANAGEMENT OF RESISTANT REFRACTORY CML
		Jorge Cortes, MD
10:55		HDAC INHIBITORS: ENHANCING THE EFFICACY OF ANTI-MYELOMA DRUGS
		James Berenson, MD
11:10		CPX 351 IN ACUTE LEUKEMIA
		Eric Feldman, MD
11:25		MAYO RISK STRATIFICATION FOR MULTIPLE MYELOMA
		Preshant Kapoor, MD
11:40		FOSTAMATINIB DISODIUM (R788) IN ITP AND B CELL LYMPHOMAS
		Jonathan Friedberg, MD
11:55		UPDATE ON LBH 589 HISTONE DEACETYLASE ACTIVITY IN LYMPHOMA
12:05		Lunch & Presentations
		FIVE YEARS WITH PROTEASOME INHIBITORS THE BACKBONE OF MEYLOMA THERAPY
		Kenneth Anderson, MD
		Sergio Giralt MD

		AFTERNOON SESSION
		GI CANCERS
		Moderators: Jordan Berlin, MD, Howard S. Hochster, MD,
1:50		PANITUMUMAB AND COMBINATION CHEMOTHERAPY IN FIRST AND SECOND LINE THERAPY OF CRC CANCER
		Emily Chan, MD
2:05		CEDIRANIB AN ACTIVE VEGF INHIBITOR IN COLORECTAL CANCER
		Paolo Hoff, MD
2:20		COLORECTAL CANCER SCREENING: WHERE ARE WE IN 2009?
		Steven Itzkowitz, MD
2:35		TOGA, TOGA, TOGA: THE STORY OF TRASTUZUMAB IN HER2-POSITIVE GASTRIC CANCER
		Charles D. Blanke, MD
2:50		C-MET INHIBITOR THERAPY IN GASTRIC CANCER
		Manish Shah, MD
3:00		Coffee Time
3:30		GEMCITABINE+ NAB-PACLITAXEL IN SPARC IN PANCREATIC CANCER
		Ramesh Ramanathan, MD
3:40		OVERVIEW OF APPENDICEAL CARCINOMAS
		Heine Hansen, MD
3:55		SURVIVAL IN ADVANCED BILIARY TRACT CANCER
		Juan Valle, MD
4:05		HEDGEHOG PATHWAY IN GI CANCER
		Deirdre Cohen, MD
4:20		mTOR INHIBITION IN GI CANCER
		Johanna Bendell, MD
4:35		VEGF INHIBITION IN NEUROENDOCRINE TUMORS OF GI TRACT
		Jordan Berlin, MD
4:50		Discussion
6:00		Reception
7 - 9 pm		DINNER AND PRESENTATIONS
		UPDATES IN MANTLE CELL LYMPHOMA
		John P. Leonard, MD


THURSDAY, NOVEMBER 12
7:00am		BREAKFAST WITH THE PROFESSORS
		NEW DATA ON OPTIMIZING TAXANE USE IN METASTATIC BREAST CANCER
		Andrew Seidman, M.D.
		OVERVIEW OF PARP ACTIVITY IN SOLID TUMORS Merrill Egorin, MD
		Morning SESSION
		Moderators: Franco M. Muggia, MD, Carmel Cohen, MD
8:00		RECURRENT OVARIAN CANCER: NEW DEVELOPMENTS
		Franco Muggia, MD
8:15		CURRENT CLINICAL TRIALS IN OVARIAN CANCER
		Thomas Herzog, MD
8:30		OVERVIEW OF NATIONAL AND INTERNATIONAL CLINICAL TRIALS
		William McGuire, MD
8:45		MOVING BEYOND STANDARD CARE: NOVEL TREATMENTS IN GYNECOLOGIC MALIGNANCIES
		Don Dizon, MD
9:00		A TARGETED THERAPY FOR RELAPSED OVARIAN CANCER
		Ursula Matulonis, M.D.
9:15		BRCA FUNCTION: A KEY FACTOR IN DETERMINING OUTCOME IN OVARIAN CANCER
		Tamar Safra, M
9:30		THE ROLE OF PARP INHIBITORS IN OVARIAN CANCER TREATMENT
		Hilary Calvert, MD
9:45		Discussion
10:00		Coffee Time
		MELANOMA
10:30		BIOMARKER LINKS ENHANCED RESPONSE TO OBLIMERSEN SODIUM
		Sanjiv Agarwala, MD
10:45		PROSPECTIVE ANALYSIS OF BRAIN METASTASES IN MELANOMA
		Iman Osman
10:55		WEB-BASED PROGNOSTIC INDICATOR FOR MALIGNANT MELANOMA
		Charles M. Balch, MD
11:10		Discussion
		HEAD & NECK CANCER
11:25		ACTIVITY OF C225 IN HEAD AND NECK CANCER
		Walter Curran, MD
		SARCOMA
11:40		TARGETING TUMOR HYPOXIA WITH TH-302: MONOTHERAPY & CHEMOTHERAPY: SARCOMAS AND OTHER SOLID TUMORS
		Sant P Chawla MD
11:50		Discussion
12 Noon		Lunch & Presentations
		GENE EXPRESSION PROFILE
		Role in Node Negative and Node Positive BC
		Harold Burstein, MD, PhD
		Predicting Colon Cancer Recurrence Risk
		Norman Wolmark, MD
1:30		EZRA M. GREENSPAN MEMORIAL LECTURE
		SUCCESSES IN PHASE I TRIALS USING GENOMIC AND CLINICAL CONTEXTS OF VULNERABILITY
		Daniel Von Hoff, MD
		AFTERNOON SESSION
		BREAST CANCER
		Moderators: Seymour Cohen, MD, George Raptis, MD
1:50		IXABEPILONE: ACTIVE AGAINST TRIPLE-NEGATIVE BREAST CANCER
		Howard Burris, MD
2:05		PARP1 INHIBITION IN TRIPLE NEGATIVE BREAST CANCER
		Cynthia Osborne, MD
2:20		PI3K INHIBITORS: OVERVIEW OF A NOVEL ANTICANCER TARGET
		Howard Burris, MD
2:35		MECHANISMS OF RESISTANCE TO HER2 KINASE INHIBITORS
		Neil Spector, MD
2:50		HER3 MEASUREMENT IN BC AND CLINICAL OUTCOMES
		Allan Lipton, MD
3:05		Coffee Time
3:35		IMC-A12 ALONE OR COMBINED WITH ANTIESTROGENS FOR PROGRESSION ON ANTIESTROGEN THERAPY
		William Gradishar, MD
3:50		NOVEL ANTI-HER2 THERAPIES: AN UPDATE ON TRASTUZUMAB-DM1
		Harold Burstein, MD
4:05		NOVEL TARGETED THERAPIES IN HER2 NEGATIVE METASTATIC BREAST CANCER
		Susan Dent, MD
4:30		Discussion
		THYROID
4:45		NEW ADVANCES IN THE TREATMENT OF ADVANCED THYROID CANCER
		Marcia Brose, MD
4:55		Discussion
7 - 9pm		Dinner and Presentation
		UPDATE ON THE AVANT STUDY
		Paulo Hoff, MD

FRIDAY, NOVEMBER 13
		Breakfast with the Professors
		Chair: Steven Burakoff, MD
7:00		IMMUNOTHERAPY: CONTINUUM OF PROGRESS
		Steven Burakoff, MD
7:45		Discussion
		MORNING SESSION
		URO-ONCOLOGY
		Moderators: Anna C Ferrari, MD, William K. Oh Prostate
		Prostate
8:00		IMATINIB AND DOCETAXEL PHASE II STUDY
		Gurkamal Chatta, MD
8:15		DOCETAXEL AND LENALIDOMIDE TRIAL IN PROSTATE CA
		Daniel Petrylak, MD
8:30		VACCINE THERAPY FOR PROSTATE CANCER
		Anna Ferrari, MD
8:45		AGENTS AND PHASE II PROSTATE CANCER CLINICAL TRIALS IN DEVELOPMENT
		Celestia Higano, MD
9:00		NEOADJUVANT DOCETAXEL & BEVACIZUMAB IN HR LOCALIZED PROSTATE CANCER: WHAT ARE BEST ENDPOINTS OF EFFICACY?
		William K. Oh, M.D.
		Renal
9:15		DOXORUBICIN AND GEMCITABINE IN METASTATIC RENAL CELL CARCINOMA WITH SARCOMATOID FEATURES
		Naomi Haas, MD
9:30		PERIFOSINE, A NOVEL AKT INHIBITOR: ACTIVITY IN METASTATIC RENAL CANCER
		Thomas Hutson, DO, PharmD
9:45		Discussion
10:00		Coffee Time
		LUNG CANCER
		Moderators Chandra Belani, M.D, Roman Perez-Soler, MD Novel Agents in Lung Cancer
10:15		ABT-888: AN ACTIVE PARP1 INHIBITOR
		Suresh Ramalingam, MD
10:25		GDC-0449
		Patricia LoRusso, MD
10:35		VORINOSTAT IN COMBINATION WITH CHEMOTHERAPY FOR NSCLC
		Chandra Belani, MD
10:45		SALIRASIB IN ADVANCED KRAS MUTANT NON-SMALL CELL LUNG CANCER
		Gregory J. Riely, MD
		NSCLC: Changing Treatment Paradigms
11:00		EGFR RESISTANCE AND BIOMARKERS
		Roman Perez-Soler, MD
11:15		PERSONALIZED CHEMOTHERAPY FOR NSCLC
		George Simon, MD
11:30		SURGICAL UPDATE ON NON-SMALL CELL LUNG CANCER & MALIGNANT PLEURAL MESOTHELIOMA
		Jessica Donington, MD
11:45		Discussion
12 Noon		LUNCH AND SPECIAL PRESENTATION
		MAINTENANCE THERAPY IN ADVANCED NSCLC: STATE OF THE ART OR STATE OF CONFUSION?
		Chandra Belani, MD, Cory Langer, MD
		KRAS MUTATIONS AND SELECTION OF TARGETED AGENTS IN NSCLC
		George Blumenschein, MD
		AFTERNOON SESSION
1:15		JUDAH FOLKMAN MEMORIAL LECTURE AN ODE TO A PIONEER
		Kathy D. Miller, MD
		DIVERSE THERAPEUTICS
		Moderators: Sylvia Adams, MD, Edward Ambinder, MD
1:35		UNKNOWN PRIMARY TUMOR: DO NEW DIAGNOSTIC METHODS INFLUENCE TREATMENT?
1:45		Anne Kristine Moelller, MD
1:55		CARFILZOMIB ACTIVITY IN SOLID TUMORS
		Jeffrey Infante, MD
2:05		FUNCTIONAL CT EVALUATION OF EVEROLIMUS AND BEVACIZUMAB IN NEUROENDOCRINE TUMORS
		James Yao, MD
2:15		BEVACIZUMAB FOR RECURRENT MALIGNANT GLIOMA
		Alexis Demopoulos, MD
2:40		IMMUNOGENICITY OF MONTANIDE ISA 51 ADJUVANT VERSUS CYTOKINE-MATURED DENDRITIC CELLS IN MELANOMA VACCINES
		Sylvia Adams, MD
2:40		CLINICAL TRIALS WITH THE NOVEL VDA PLINABULIN (NPI-2358)
		Monica Mita, MD
2:50		CTEP CLINICAL TRIALS
		John Wright, MD
3:05		EVOLVING PRACTICE PATTERNS IN ONCOLOGY
		Joseph Bailes, MD
3:15		Coffee Time
		WHAT EVERY ONCOLOGIST MUST KNOW ABOUT ONCOLOGY EHRS
		Chair: Edward M. Ambinder
3:30		OVERVIEW
		Edward P. Ambinder, MD
3:35		THE ASCO/NCI DEFINITION OF THE ONCOLOGY EHR
		Peter Yu, MD
3:45		PRINCIPLES OF SAFE PRACTICE: USING AN ONCOLOGY EHR FOR CHEMOTHERAPY ORDERING, PREPARATION & ADMINISTRATION
		Larry Shulman, MD
3:55		THE NCI’S caBIG AND THE ONCOLOGIST
		To Be Announced
4:05		CHOOSING THE RIGHT EHR FOR YOUR PRACTICE
		Carolyn Hartley
4:15		Discussion
4:25		LATE BREAKING DEVELOPMENTS
7-9pm		Dinner and Presentation
		AML IN THE OLDER PATIENT
		Harry P. Erba, MD

SATURDAY, NOVEMBER 14
		New Perspectives in Oncology Practice
8:00		Expanding role of targeted therapies in leukemia and lymphoma
		Karen Stanley, RN, MSN, AOCN, FAAN Immediate Past President, Oncology Nursing Society; Consultant, end-of-life and cancer care issues
8:40		Sexuality and Cancer - Egg Banking
		John K. Critser, PhD
		Professor of Veterinary Pathobiology University of Missouri School of Medicine
9:00		Nutritional Management of Chemotherapy Side Effects
		Lynn Goldstein, MS, RD, CDN Clinical Dietician, New York Presbyterian Hospital Center for ALS Care, Beth Israel Hospital, NY
9:20		Cost of Cancer Medications in a Slumping Economy
		Ricky Newton, CPA Cancer Specialists of Tidewater Virginia
9:40		Sarcomas
		Denise Reinke, APRN, BC, AOCN Sarcoma Nurse Practitioner University of Michigan Comprehensive Cancer Center and Administrative Director of SARC (Sarcoma Alliance for Research through Collaboration) Ann Arbor, MI
10:20		Keynote Speaker: David Balch
		You Can Handle More Than you Think You Can Caregiver, Consultant, President of The Patient/Partner Project
11:00		Oncologic Emergencies
		Maura Polansky, MS, PA-C MD Anderson Cancer Center Houston, TX
11:20		Multidisciplinary Issues in Head and Neck Cancers
		Tara DiFabio, MSN RN CORLN
		Head and Neck Oncology Nurse Practitioner Thomas Jefferson University
11:40		Alternative Coping Mechanisms
		Carla Mariano, MSW New York University College of Nursing
12:00 pm		Lunch Break
1:15		Gastric-Esophageal Cancers
		Joyce Griffin-Sobel, PhD, RN, AOCN, APRN-BC, CNE, ANEF Associate Dean Hunter College School of Nursing New York, NY
1:35		Clinical Trials in Oncology Care
		Shannon Holloway, PA-C, MHS Clinical Trials Coordinator Center for Liver Disease and Transplantation New York Presbyterian Weill Cornell Medical Center New York, NY
1:55		Cancer Survival from the Patient’s Perspective
		Pamela Herman, cancer survivor Michael Fisch, MD MD Anderson Cancer Center Houston, TX Arden Moulton, MSW Mt. Sinai Medical Center Gynecologic Cancer Center New York. NY
2:15		Latest Guidelines and Control Issues for Erythropoetins
		Cheryl Gilmartin, PharmD Clinical Assistant Professor Ambulatory Care Pharmacy University of Illinois College of Pharmacy Chicago, IL
2:35		Lung Cancer in Women
		Suzanne Walker, RN University of Pennsylvania Health Sciences Center
2:55		Biologics in Cancer Treatment
		Gloria Smith, Ph.D., FAAN, FRCN Retired vice president of the W.K. Kellogg Foundation and American Academy of Nursing Living Legend
3:15		The New Technology in Oncology Practice
		Edward Ambinder, MD Medical Oncologist Mt. Sinai School of Medicine New York, NY
3:35		Adherence to Oral Medications
		Tracy Gosselin, RN Administrative Director Department of Radiation Oncology Duke University Medical Center Durham, NC.

Conference Management Director: Jaclyn Silverman email: Jaclyn.silverman@mssm.edu | Phone 212 866 2813


	November 10-14, 2009 Marriott Marquis, New York City